The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Moxetumomab pasudotox (Brand name: Lumoxiti)
- Manufactured by
AstraZeneca Pharmaceuticals LP
FDA-approved indication: September 2018, moxetumomab pasudotox (Lumoxiti) was approved for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
National Library of Medicine Drug Information Portal